Articles

For all the talk of artificial intelligence being in a bubble, Bank of America’s derivatives strategists say there’s one missing element.

Olympic legend Simone Biles is no doubt hoping that good things come to those who wait—particularly when that wait has stretched on for more than two years.

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.

Despite expectations for a mixed second quarter, some analysts are staying confident on IBM’s software segment

In the span of about a week, Opendoor Technologies Inc. has gone from a struggling former pandemic-era darling to the talk of the U.S. equity market.

A weaker dollar, the global AI race and plans for ramped-up government spending abroad are all reasons why global equities can shine in the months and years ahead.

The estimate comes from the nonpartisan Congressional Budget Office, which President Trump and Republicans have attacked.

Medicare Advantage could become the default insurance program for all older adults

Americans agree — across political, economic and generational lines — that the program is worth saving.

For anybody hunting for parallels between contemporary markets and 1999, BTIG’s Jonathan Krinsky has a chart that might be of interest.

With less than two weeks to go before country-specific tariffs could rise sharply, the Trump administration is drawing a lot of questions about what’s ahead.

Investors will be questioning the chip maker’s strategy for the future more than worrying about its second quarter earnings results, Bernstein analysts say